MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,493,788
Net Income
-$8,923,846
Net Profit Margin
-597.40%
EPS
-$0.08
Unit: Dollar
Revenue Breakdown
Gross product revenue
Gross-to-net adjustments
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
1,493,788
1,667,298
3,944,111
-
Cost of revenues
491,843
328,878
789,208
-
Gross profit
1,001,945
1,338,420
3,154,903
-
Research and development
218,496
1,079,354
1,018,352
1,076,136
Amortization of in-process research and development
1,720,312
1,720,312
573,438
-
General and administrative
4,219,163
23,625,639
2,859,339
1,337,244
Stock-based compensation general and administrative
3,560,791
3,526,710
3,956,050
2,298,132
Total operating expenses
9,718,762
29,952,015
8,407,179
4,711,512
Operating loss
-8,716,817
-28,613,595
-5,252,276
-4,687,001.25*
Interest income
96,848
43,721
28,288
9,093.25*
Gain on sale of new jersey net operating losses
-
1,762,000
-
-
Amortization of deferred financing costs
179,492
-
-
-
Interest expense
231,732
33,031
45,841
54,508*
Total other income (expense), net
-314,376
1,772,690
-17,553
-45,414.75*
Loss before income taxes
-9,031,193
-26,840,905
-5,269,829
-4,732,416
Income tax expense (benefit)
-107,347
-231,210
264,240
264,240
Net loss
-8,923,846
-26,609,695
-5,534,069
-4,996,656
Basic EPS
-0.08
-0.27
-0.06
-0.064
Diluted EPS
-0.08
-0.27
-0.06
-0.064
Basic Average Shares
107,890,452
100,027,204
87,462,385
78,414,670
Diluted Average Shares
107,890,452
100,027,204
87,462,385
78,414,670
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$8,923,846
(-66.18%↓ Y/Y)
Income tax expense
(benefit)
-$107,347
(-140.62%↓ Y/Y)
Gross product revenue
$1,708,560
Loss before income
taxes
-$9,031,193
(-76.88%↓ Y/Y)
Revenues
$1,493,788
Gross-to-net adjustments
$214,772
Operating loss
-$8,716,817
(-76.28%↓ Y/Y)
Total other income
(expense), net
-$314,376
Gross profit
$1,001,945
Interest income
$96,848
Cost of revenues
$491,843
Total operating
expenses
$9,718,762
(96.54%↑ Y/Y)
Interest expense
$231,732
(44.15%↑ Y/Y)
Amortization of deferred
financing costs
$179,492
General and
administrative
$4,219,163
(124.25%↑ Y/Y)
Stock-based compensation
general and...
$3,560,791
(67.55%↑ Y/Y)
Amortization of in-process
research and development
$1,720,312
Research and development
$218,496
(-76.71%↓ Y/Y)
Buy us a coffee
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)